Interventions for actinic keratoses
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Actinic keratoses are a skin disease caused by long-term sun exposure, and their lesions have the potential to develop into squamous cell carcinoma. Treatments for actinic keratoses are sought for cosmetic reasons, for the relief of associated symptoms, or for the prevention of skin cancer development. Detectable lesions are often associated with alteration of the surrounding skin (field) where subclinical lesions might be present. The interventions available for the treatment of actinic keratoses include individual lesion-based (e.g. cryotherapy) or field-directed (e.g. topical) treatments. These might vary in terms of efficacy, safety, and cosmetic outcomes. OBJECTIVES: To assess the effects of topical, oral, mechanical, and chemical interventions for actinic keratosis. SEARCH METHODS: We searched the following databases up to March 2011: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library, MEDLINE (from 2005), EMBASE (from 2010), and LILACS (from 1982). We also searched trials registers, conference proceedings, and grey literature sources. SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing the treatment of actinic keratoses with either placebo, vehicle, or another active therapy. DATA COLLECTION AND ANALYSIS: At least two authors independently abstracted data, which included adverse events, and assessed the quality of evidence. We performed meta-analysis to calculate a weighted treatment effect across trials, and we expressed the results as risk ratios (RR) and 95% confidence intervals (CI) for dichotomous outcomes (e.g. participant complete clearance rates), and mean difference (MD) and 95% CI for continuous outcomes (e.g. mean reduction in lesion counts). MAIN RESULTS: We included 83 RCTs in this review, with a total of 10,036 participants. The RCTs covered 18 topical treatments, 1 oral treatment, 2 mechanical interventions, and 3 chemical interventions, including photodynamic therapy (PDT). Most of the studies lacked descriptions of some methodological details, such as the generation of the randomisation sequence or allocation concealment, and half of the studies had a high risk of reporting bias. Study comparison was difficult because of the multiple parameters used to report efficacy and safety outcomes, as well as statistical limitations. We found no data on the possible reduction of squamous cell carcinoma.The primary outcome 'participant complete clearance' significantly favoured four field-directed treatments compared to vehicle or placebo: 3% diclofenac in 2.5% hyaluronic acid (RR 2.46, 95% CI 1.66 to 3.66; 3 studies with 420 participants), 0.5% 5-fluorouracil (RR 8.86, 95% CI: 3.67 to 21.44; 3 studies with 522 participants), 5% imiquimod (RR 7.70, 95% CI 4.63 to 12.79; 9 studies with1871 participants), and 0.025% to 0.05% ingenol mebutate (RR 4.50, 95% CI 2.61 to 7.74; 2 studies with 456 participants).It also significantly favoured the treatment of individual lesions with photodynamic therapy (PDT) compared to placebo-PDT with the following photosensitisers: aminolevulinic acid (ALA) (blue light: RR 6.22, 95% CI 2.88 to 13.43; 1 study with 243 participants, aminolevulinic acid (ALA) (red light: RR 5.94, 95% CI 3.35 to 10.54; 3 studies with 422 participants), and methyl aminolevulinate (MAL) (red light: RR 4.46, 95% CI 3.17 to 6.28; 5 studies with 482 participants). ALA-PDT was also significantly favoured compared to cryotherapy (RR 1.31, 95% CI 1.05 to 1.64).The corresponding comparative risks in terms of number of participants completely cleared per 1000 were as follows: 313 with 3% diclofenac compared to 127 with 2.5% hyaluronic acid; 136 with 0.5% 5-fluorouracil compared to 15 with placebo; 371 with 5% imiquimod compared to 48 with placebo; 331 with ingenol mebutate compared to 73 with vehicle; 527 to 656 with ALA/MAL-PDT treatment compared to 89 to 147 for placebo-PDT; and 580 with ALA-PDT compared to 443 with cryotherapy.5% 5-fluorouracil efficacy was not compared to placebo, but it was comparable to 5% imiquimod (RR 1.85, 95% Cl 0.41 to 8.33).A significant number of participants withdrew because of adverse events with 144 participants affected out of 1000 taking 3% diclofenac in 2.5% hyaluronic acid, compared to 40 participants affected out of 1000 taking 2.5% hyaluronic acid alone, and 56 participants affected out of 1000 taking 5% imiquimod compared to 21 participants affected out of 1000 taking placebo.Based on investigator and participant evaluation, imiquimod treatment and photodynamic therapy resulted in better cosmetic outcomes than cryotherapy and 5-fluorouracil. AUTHORS' CONCLUSIONS: For individual lesions, photodynamic therapy appears more effective and has a better cosmetic outcome than cryotherapy. For field-directed treatments, diclofenac, 5-fluorouracil, imiquimod, and ingenol mebutate had similar efficacy, but their associated adverse events and cosmetic outcomes are different. More direct comparisons between these treat
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Pariser, D. M., Lowe, N. J., Stewart, D. M., Jarratt, M. T., Lucky, A. W., Pariser, R. J., & Yamauchi, P. S. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.49 · Cited by 302
Freeman, M., Vinciullo, C., Francis, D., Spelman, L., Nguyen, R., Fergin, P., Thai, K., Murrell, D., Weightman, W., Anderson, C., et al. (2003) · Journal of Dermatological Treatment · doi:10.1080/09546630310012118 · Cited by 285
Piacquadio, D. J., Chen, D. M., Farber, H. F., Fowler, Jr., Glazer, S. D., Goodman, J. J., Hruza, L. L., Jeffes, E. W. B., Ling, M. R., Phillips, T. J., et al. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.1.41 · Cited by 239
Tarstedt, M., Rosdahl, I., Berne, B., Svanberg, K., & Wennberg, A. (2005) · Acta Dermato-Venereologica · doi:10.1080/00015550510032887 · Cited by 196
Apalla, Z., Sotiriou, E., Chovarda, E., Lefaki, I., Devliotou-Panagiotidou, D., & Ioannides, D. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09492.x · Cited by 116
Wennberg, A.-M., Stenquist, B., Stockfleth, E., Keohane, S., Lear, J. T., Jemec, G., Mork, C., Christensen, E., Kapp, A., Solvsten, H., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318180731e · Cited by 112
The actinic keratosis: A perspective and update
SCHWARTZ, R. A. (1997) · Dermatologic Surgery · doi:10.1111/j.1524-4725.1997.tb00438.x · Cited by 80
Cited by
Rai, S., Pandey, V., & Rai, G. (2017) · Nano Reviews & Experiments · doi:10.1080/20022727.2017.1325708 · Cited by 301
Photodynamic Therapy: A Clinical Consensus Guide
Ozog, D. M., Rkein, A. M., Fabi, S. G., Gold, M. H., Goldman, M. P., Lowe, N. J., Martin, G. M., & Munavalli, G. S. (2016) · Dermatologic Surgery · doi:10.1097/dss.0000000000000800 · Cited by 276
Current evidence and applications of photodynamic therapy in dermatology
Lin, J., & Wan, M. T. (2014) · Clinical, Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s35334 · Cited by 248
A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis
Reinhold, U. (2017) · Future Oncology · doi:10.2217/fon-2017-0247 · Cited by 46
Molina-García, M., Malvehy, J., Granger, C., Garre, A., Trullàs, C., & Puig, S. (2022) · Dermatology and Therapy · doi:10.1007/s13555-021-00644-3 · Cited by 15
Metadata
- Authors
- Gupta, A. K., Paquet, M., Villanueva, E., & Brintnell, W.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-12-12
- Volume
- 12
- Pages
- CD004415-CD004415
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1933295591
- Cited by
- 224
- References
- 9
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.